Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-mutated Non-small-cell Lung Cancer

Overview

Journal Nat Commun

Specialty Biology

Date 2017 Mar 14

PMID 28287083

Citations 159

Authors

Ken Uchibori

Naohiko Inase

Mitsugu Araki

Mayumi Kamada

Shigeo Sato

Yasushi Okuno

Naoya Fujita

Ryohei Katayama

Affiliations

Soon will be listed here.

Abstract

Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib. Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance. In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo. Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR. The structure-activity relationship analysis reveals the key component in brigatinib to inhibit the triple-mutant EGFR. The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression. Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.

Citing Articles

[ Turcz. alleviates antibiotic-associated diarrhea in mice by modulating gut microbiota structure and regulating the EGFR/PI3K/Akt signaling pathway].

Xu H, Zhang F, Huang Y, Yao Q, Guan Y, Chen H Nan Fang Yi Ke Da Xue Xue Bao. 2025; 45(2):285-295.

PMID: 40031972 PMC: 11875858. DOI: 10.12122/j.issn.1673-4254.2025.02.09.

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

Afatinib and Necitumumab in -Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.

Myall N, Whisenant J, Neal J, Iams W, Reckamp K, York S JTO Clin Res Rep. 2025; 6(2):100757.

PMID: 39866193 PMC: 11759541. DOI: 10.1016/j.jtocrr.2024.100757.

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.

Zhou F, Guo H, Xia Y, Le X, Tan D, Ramalingam S Nat Rev Clin Oncol. 2024; 22(2):95-116.

PMID: 39614090 DOI: 10.1038/s41571-024-00971-2.

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.

Ntzifa A, Marras T, Kallergi G, Kotsakis A, Georgoulias V, Lianidou E Front Oncol. 2024; 14:1435537.

PMID: 39497713 PMC: 11532185. DOI: 10.3389/fonc.2024.1435537.

References

Giaccone G . Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005; 23(14):3235-42. DOI: 10.1200/JCO.2005.08.409. View

Ercan D, Choi H, Yun C, Capelletti M, Xie T, Eck M . EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res. 2015; 21(17):3913-23. PMC: 4791951. DOI: 10.1158/1078-0432.CCR-14-2789. View

Johnson M, Riely G, Rizvi N, Azzoli C, Kris M, Sima C . Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J Thorac Oncol. 2011; 6(6):1128-31. PMC: 3230574. DOI: 10.1097/JTO.0b013e3182161508. View

Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M . Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 2006; 12(19):5764-9. DOI: 10.1158/1078-0432.CCR-06-0714. View

Thress K, Paweletz C, Felip E, Cho B, Stetson D, Dougherty B . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21(6):560-2. PMC: 4771182. DOI: 10.1038/nm.3854. View

Jiang T, Zhou C . Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. Transl Lung Cancer Res. 2015; 3(6):370-2. PMC: 4367669. DOI: 10.3978/j.issn.2218-6751.2014.08.02. View

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2009; 11(2):121-8. DOI: 10.1016/S1470-2045(09)70364-X. View

Duong-Ly K, Devarajan K, Liang S, Horiuchi K, Wang Y, Ma H . Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Rep. 2016; 14(4):772-781. PMC: 4740242. DOI: 10.1016/j.celrep.2015.12.080. View

10.

Camidge D, Pao W, Sequist L . Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11(8):473-81. DOI: 10.1038/nrclinonc.2014.104. View

11.

Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-43. DOI: 10.1126/science.1141478. View

12.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

13.

Planchard D, Loriot Y, Andre F, Gobert A, Auger N, Lacroix L . EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015; 26(10):2073-8. DOI: 10.1093/annonc/mdv319. View

14.

Hess B, Kutzner C, van der Spoel D, Lindahl E . GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput. 2015; 4(3):435-47. DOI: 10.1021/ct700301q. View

15.

Wang J, Wolf R, Caldwell J, Kollman P, Case D . Development and testing of a general amber force field. J Comput Chem. 2004; 25(9):1157-74. DOI: 10.1002/jcc.20035. View

16.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

17.

Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J . The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016; 22(22):5527-5538. DOI: 10.1158/1078-0432.CCR-16-0569. View

18.

Ohashi K, Sequist L, Arcila M, Moran T, Chmielecki J, Lin Y . Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012; 109(31):E2127-33. PMC: 3411967. DOI: 10.1073/pnas.1203530109. View

19.

Riely G, Kris M, Zhao B, Akhurst T, Milton D, Moore E . Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007; 13(17):5150-5. DOI: 10.1158/1078-0432.CCR-07-0560. View

20.

Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H . Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2012; 24(1):54-9. DOI: 10.1093/annonc/mds214. View